ReviewCureus2026
RNA Capping, Replication Complex Assembly, and Translational Regulation in Chikungunya Virus: Molecular Mechanisms and Antiviral Opportunities.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chikungunya virus (CHIKV) is an emerging mosquito-borne alphavirus that has become a significant global public health concern due to its rapid spread and the debilitating acute and chronic joint pain (arthralgia) it causes. Understanding the molecular events that regulate CHIKV RNA synthesis and gene expression is essential for identifying vulnerable stages in the viral life cycle and guiding the development of targeted therapies. This narrative review summarises key aspects of CHIKV molecular biology, focusing on RNA capping, genome replication, and translation. CHIKV RNA capping is primarily facilitated by non-structural protein 1 (nsP1), which has both methyltransferase and guanylyl transferase activities. These activities are necessary for producing the 5' type-0 cap structure (m⁷GpppN), which stabilises viral RNA, enhances translation efficiency, and aids in immune evasion. Viral genome replication takes place within membrane-derived replication spherules that compartmentalise replication complexes composed of nsP1-nsP4 and host cofactors, protecting RNA intermediates from detection by the innate immune system. The RNA-dependent RNA polymerase nsP4 drives the synthesis of negative-strand templates, followed by the amplification of positive-sense genomic RNA and the transcription of 26S sub-genomic RNA for structural protein production. CHIKV also modifies host translation and antiviral signalling to maintain efficient viral protein synthesis. These findings demonstrate that nsP1, nsP2, and nsP4 are promising antiviral targets. They emphasise the importance of understanding CHIKV's molecular mechanisms to develop effective therapeutic strategies against CHIKV and related alphaviruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.